Early Detection and Gemcitabine/Cisplatin Combination Positively Effect Survival in Sarcomatoid Carcinoma of the Urinary Bladder |
Baseskioglu, Barbaros
(Department of Urology, ESOGU Medical Faculty)
Duman, Berna Bozkurt (Department of Medical Oncology, Cukurova University Medical Faculty) Kara, I. Oguz (Department of Medical Oncology, Cukurova University Medical Faculty) Can, Cavit (Department of Urology, ESOGU Medical Faculty) Yildirim, Mustafa (Antalya Education and Research Hospital) Acikalin, Mustafa (Department of Pathology, ESOGU Medical Faculty) |
1 | Doghri R, Sellami R, Driss M, et al (2012). Sarcomatoid carcinoma of the urinary bladder. Tunis Med, 90, 183-4. |
2 | Eble JN, Sauter G, Epstein JI, Sesterhenn I (eds): "Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs." IARC Press: Lyon, 2004. |
3 | Escudier B, Pluzanska A, Koralewski P et al (2007). AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet, 370, 2103-11. DOI |
4 | Froehner M, Gaertner HJ, Manseck A, Wirth MP (2001). Durable complete remission of metastatic sarcomatoid carcinoma of the bladder with cisplatin and gemcitabine in an 80-year-old man. Urology, 58, 799. |
5 | Ikegami H, Iwasaki H, Ohjimi Y, et al (2000). Sarcomatoid carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical analysis of 14 patients. Hum Pathol, 31, 332-40. DOI ScienceOn |
6 | Jemal A, Siegel R, Xu J, Ward E (2009). Cancer Statistics, 2010. CA Cancer J Clin, 59, 225-49. DOI ScienceOn |
7 | Jue Wanga J, Gillaspiea C, Kunadharajua R, Talmon GA, Enke C (2011). Sarcomatoid urothelial carcinoma: a single cancer center experience. World J Oncol, 2, 175-80 |
8 | Lopez-Beltran A, Pacelli A, Rothenberg HJ, et al (1998). Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. J Urol, 159, 1497-503. DOI ScienceOn |
9 | Mansure JJ, Nassim R, Chevalier S, et al (2009). Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol Ther, 8, 2339-47. |
10 | Nimeh T, Kuang W, Levin HS, Klein EA (2002). Sarcomatoid transitional cell carcinoma of bladder managed with transurethral resection alone. J Urol, 167, 641-2. DOI |
11 | Nishikawa R, Fujimura M, Endo Y, et al (2011). A case of carcinosarcoma of the urinary bladder). Hinyokika Kiyo, 57, 199-202. |
12 | Singh NG, Mannan AA, Kahvic M, Sara YA (2011). Sarcomatoid carcinoma of the urinary bladder: a report of two cases. Indian J Pathol Microbiol, 54, 400-1. DOI |
13 | Stamatiou K, Galariotis N, Michailidis I, et al (2010). Sarcomatoid carcinoma of the urinary bladder: a clinicopathological study of 4 cases and a review of the literature. Korean J Urol, 51, 724-8. DOI |
14 | Sung MT, Wang M, MacLennan G, et al (2007). Histogenesis of sarcomatoid urothelial carcinoma of the urinary bladder: evidence for a common clonal origin with divergent differentiation. J Pathol, 211, 420-30. DOI |
15 | Tickoo SK, Milowsky MI, Dhar N, et al (2010). Hypoxiainducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications. BJU Int. |
16 | Young RH (1987). Carcinosarcoma of the urinary bladder. Cancer, 59, 1333-9. DOI |
17 | Torenbeek R, Blomjous CE, de Bruin PC, et al (1994). Sarcomatoid carcinoma of the urinary bladder: clinicopathologic analysis of 18 cases with immunohistochemical and electron microscopic findings. Am J Surg Pathol, 18, 241-9. DOI |
18 | Wang J, Wang FW, LaGrange CA, et al (2010). Clinical features of sarcomatoid (carcinosarcoma) of the urinary bladder: analysis of 221 cases. Sarcoma, 2, 454792. |
![]() |